|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cohort | Type of MS | 4-SNP signature status | Total | Difference in mean ARR: OL phase (on treatment) vs DB phase (on placebo) |
| 9001 | RRMS | Negative | 22 | -78% |
| Positive | 15 | -70% |
| 9003 | Negative | 27 | -40% |
| Positive | 21 | -70% |
| GALA | Negative | 147 | -51% |
| Positive | 196 | -58% |
| PreCISe | CIS | Negative | 53 | -49% |
| Positive | 66 | -58% |

**Additional File 11: Change in ARR among placebo patients who were switched to Copaxone treatment in the OL phase.**